Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Solid Neoplasms × pembrolizumab × Clear all

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 106 Melanoma 82 Neoplasms 70 Colorectal Neoplasms 56 Squamous Cell Carcinoma of Head and Neck 53 Neoplasm Metastasis 49 Triple Negative Breast Neoplasms 43 Carcinoma, Renal Cell 42 Breast Neoplasms 37 Lung Neoplasms 32 Ovarian Neoplasms 30 Pancreatic Neoplasms 28 Urinary Bladder Neoplasms 24 Head and Neck Neoplasms 24 Stomach Neoplasms 23 Carcinoma, Transitional Cell 22 Parkinson Disease 4, Autosomal Dominant Lewy Body 21 Endometrial Neoplasms 20 Uterine Cervical Neoplasms 19 Carcinoma, Hepatocellular 15 Esophageal Neoplasms 14 Lymphoma 13 Recurrence 12 Prostatic Neoplasms 12 Carcinoma, Squamous Cell 12 Kidney Neoplasms 11 Sarcoma 9 Lymphoma, Large B-Cell, Diffuse 9 Cholangiocarcinoma 9 Solid Tumor 8

Interventions

pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03364049 2021-11-15

MK-7162-002

Merck Sharp & Dohme LLC

Phase 1 Completed

33 enrolled 19 charts

Solid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡